Abstract: TH-OR14
0.075% Capsaicin Lotion for the Treatment of Peripheral Neuropathy in ESRD Patients: A Multicenter Randomized Double-Blind Placebo-Controlled, Cross-Over Trial
Session Information
- Dialysis: Patient-Centered Interventions and Outcomes
November 03, 2022 | Location: W414, Orange County Convention Center‚ West Building
Abstract Time: 04:57 PM - 05:06 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Kittidanairuk, Parinada, Phramongkutklao Hospital, Bangkok, Thailand
- Varothai, Narittaya, Phramongkutklao Hospital, Bangkok, Thailand
- Nimkietkajorn, Veerapatr, Buddhachinaraj Phitsanulok Hospital, Phitsanulok, Thailand
Background
Neuropathic pain is one of the common symptom in chronic kidney disease (CKD) patients leads to problems in physical, mental and quality of life. Pain medications are also limited in CKD. This study aims to evaluate the effect of 0.075% capsaicin lotion in neuropathic pain, quality of life and side effect of End Stage Renal Disease (ESRD) patient required Renal Replacement Therapy (RRT).
Methods
We conducted a multicenter randomized, double-blinded, crossover, placebo controlled trial included 60 ESRD patients required RRT who had peripheral neuropathy in dialysis units in Bangkok and Phitsanulok province. The participants were randomized to received 0.075% capsaicin/placebo for 8 weeks, then crossing over to the other treatment for 8 weeks after a 2-weeks washout period. Primary outcome was the change in visual analog scale (VAS) score of pain severity. Secondary outcomes were changes in neuropathic pain scale, short-form McGill Pain questionnaire, quality of life in kidney disease using KDQOL-36 and adverse event.
Results
A total of 55 participants were enrolled, baseline VAS pain score was 6.05. After 8 weeks of capsaicin lotion, VAS score decrease 1.75 (p 0.615) after 8 weeks. Proportions of patients with pain score reductions of 50% significantly decreased in capsaicin group 23 (41%) and 14 (25.45%) in control group (p 0.022). From subgroup analysis, VAS in patients with severe pain score at start decreased significantly (p 0.021), compare to those with moderate pain score at start (p 1.000). KDQOL-36, the mean score in daily activity trend to decrease 0.25 in capsaicin group compare to 0.05 in control group (p 0.094). Capsaicin lotion was well tolerated with some local skin reactions.
Conclusion
In ESRD patients with peripheral neuropathy, 0.075% capsaicin lotion can significantly decrease pain score 50% and trend to improve daily activity aspect of quality of life in kidney disease.
Funding
- Commercial Support – Bangkok Drug Company